Allergan Restasis gets Health Canada approval
Allergan said that Restasis is the first prescription eye drop to target the underlying cause of chronic Dry Eye. Allergan claimed that Restasis helps increase the eye’s natural
Mereo BioPharma and Zydus Lifesciences subsidiary Sentynl Therapeutics have signed an option and licence agreement related to the US commercial and worldwide manufacturing rights to alvelestat, a potential oral treatment for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).